Pfizer Inc. — Income Charts
73 quarters of history · ending 2026-03-29 · SEC EDGAR
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Pfizer Inc. — SEC R-Report Segment ScorecardNEW
One card per operating segment. KPIs read the latest disclosed value (issuer-precomputed margin and YoY %, not recomputed client-side). Sparkline shows the 3-period revenue trend. Source: SEC EDGAR R-reports.
Biopharma
3-period revenue trend
Pfizer Inc. — Revenue & Assets by GeographyNEW
Per-country / per-region revenue + long-lived non-current assets sourced from the issuer's 10-K dimensional XBRL on srt:StatementGeographicalAxis.
United States
$37.1Brev
$9.7BPP&E
Developed Markets
—rev
$8.2BPP&E
International Developed Markets
$16.2Brev
International Emerging Markets
$9.3Brev
$1.5BPP&E
Pfizer Inc. — Customer & Supplier ConcentrationNEW
Major-customer and supplier-side disclosures sourced from srt:MajorCustomersAxis dimensional XBRL. Coverage is ~44% of the S&P 500 (sparser than other panels) but high-value when present — a 20%+ single-counterparty exposure is a headline business risk required to be disclosed in 10-K MD&A under Reg S-K Item 101.Largest single-counterparty concentration this period: 40%.
Customer-Side Concentration
End-customer dependence — single-customer % of revenue. NVDA Customer 1 = 25%, AVGO Major Customer 1 = 32%.
As of 2025-12-31 · 4 rows
| Counterparty | Kind | Concentration | Revenue / Spend |
|---|---|---|---|
| Three Largest US Wholesale Customers | customer | 40.0% | — |
| Mc Kesson Inc. | customer | 25.0% | — |
| Cencora Inc. | customer | 16.0% | — |
| Cardinal Health Inc. | customer | 13.0% | — |